DEBT (Tables)

12 Months Ended

Sep. 30, 2021

DEBT

Schedule of term loans

	Principal Amount
	as of date of Credit				Monthly
	Agreement		Annual		Payment
	April 30, 2021		Interest		Amount
Loan Name	(000)		Rate		(000)		Maturity Date	Use of Proceeds
Term Loan 1	$	3,980	5.20	%	$	36	March 28, 2025	Funded expansion of building on real property in Mount Vernon, IN
Term Loan 2	$	3,571	5.06	%	$	78	July 2, 2023	Funded a portion of the cash consideration for the Seventh Wave Laboratories acquisition
Term Loan 3	$	1,076	5.20	%	$	32	March 28, 2025	Funded equipment needs associated with expansion of real property in Mount Vernon, IN
Term Loan 4	$	1,001	4.63	%	$	20	November 1, 2025	Funded the cash consideration for the Smithers Avanza acquisition
Term Loan 5	$	810	4.00	%	$	17	June 30, 2025	Funded certain capital expenditures
Term Loan 6	$	2,865	4.25	%	$	56	December 31, 2025	Funded certain capital expenditures
Term Loan 7	$	1,263	4.00	%	$	28	June 1, 2025	Financed aspects of the Pre-Clinical Research Services and related real property acquisitions
Term Loan 8	$	1,853	4.00	%	$	12	December 1, 2024	Financed aspects of the Pre-Clinical Research Services and related real property acquisitions
Term Loan 9	$	10,000	3.85	%	$	184 (a)	April 30, 2026	Funded a portion of the cash consideration of the Bolder BioPATH merger
Term Loan 10	$	5,000	3.85	%	$	92 (a)	April 30, 2026	Funded a portion of the cash consideration of the HistoTox Labs acquisition
Term Loan 11	$	3,622	3.99	%	$	33	June 23, 2022	Refinanced debt with The Huntington Bank for general business purposes
Term Loan 12	$	4,832 (b)	3.85	%	$	10 (c)	December 26, 2026	Financed the acquisition of the St. Louis facility and associated expansion

(a) See Mandatory Prepayments information below

(b) Principal amount as of May 26, 2021

(c) The Monthly payment amount increases to $29 on January 1, 2022

Schedule of weighted-average assumptions used to compute the fair-value

	2021
Risk-free interest rate	1.20	%
Dividend yield	—	%
Volatility of the expected market price of the Company’s common shares	81.10	%
Maturity period (years)	6.04

Schedule of long-term debt

Long-term debt is detailed in the table below.

	As of September 30:
	2021		2020
Term Loan #1	$	3,888	$	4,230
Term Loan #2		3,255		4,004
Term Loan #3		963		1,266
Term Loan #4		920		1,115
Term Loan #5		737		920
Term Loan #6		2,590		—
Term Loan #7		1,145		1,425
Term Loan #8		1,825		1,891
Term Loan #9		9,395		—
Term Loan #10		4,697		—
Term Loan #11		3,495		3,748
Term Loan #12		3,275		—
Subtotal Term Loans		36,185		18,599
Seller Note – Bolder BioPATH		1,500		—
Seller Note – Smithers Avanza		280		650
Seller Note – Preclinical Research Services		685		752
Paycheck protection program loan		—		5,051
Convertible Senior Notes		131,673		—
		170,323		25,052
Less: Current portion		(9,656)		(5,991)
Less: Debt issue costs not amortized		(6,458)		(235)
Total Long-term debt	$	154,209	$	18,826

Schedule of maturities of long-term debt

	2022		2023		2024		2025		2026		Thereafter		Total
Long-term debt(a)	$	550	$	363	$	412	$	869	$	270	$	131,673	$	134,137

(a) excludes indebtedness to FIB repaid in November 2021. Refer to Note 16